Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in Treatment-Naïve Operable Breast Cancer
NCT00633750Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2002
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in breast cancer, sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Number of Participants Experiencing in Situ Anti-tumor Effect of Tarceva. Started Aug 2002; status: completed.
02
Drugs
erlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00633750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00633750.